In vivo (phase I) trial and in vitro efficacy of humanized anti-Tac for the prevention of rejection in renal transplant recipients.
Stock
P G
PG
Division of Transplant Surgery, University of California-San Francisco 94143-0116, USA.
Lantz
M
M
Light
S
S
Vincenti
F
F
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D006084:Graft Rejection / Q000517:prevention & control*; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D016030:Kidney Transplantation / Q000276:immunology*; D007959:Lymphocyte Culture Test, Mixed; D015375:Receptors, Interleukin-2 / Q000276:immunology
D000911:Antibodies, Monoclonal; D015375:Receptors, Interleukin-2